Anthropic reports early results from six drug development partnerships
Article timeline
The articles in this story. Times are ET.
Rohan PaulXAnthropic reports Claude is used in six drug programs and its own preclinical effortsAIAnthropic says it has deep research partnerships with six drug developers and has started its own drug discovery work, with Claude supporting multiple stages of development. Its in-house muscular dystrophy program could reach human trials as soon as late 2028, though the work is mostly preclinical. The quoted post cites about 35,000 antibody designs generated in roughly a month, and the linked Enveda example says Claude caught seven manufacturing issues human reviewers missed.
Andrew CurranXAnthropic begins drug discovery work and partners with six drug developersAIAnthropic says its scientists have spent several months in deep research partnerships with six drug developers: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. The company has also started its own drug discovery efforts. It says it has learned how Claude can support many stages of drug development and plans to scale the work substantially.
AnthropicOfficialAnthropic partners with six drug developers and begins its own drug discovery workAIAnthropic scientists have run deep research partnerships with six organizations developing new medicines over the past few months. The company has also started its own drug discovery efforts and says it has learned more about how Claude can support multiple stages of drug development. Early results are shared in a blog post at
- Anthropic ResearchOfficialPickAnthropic reports early results of Claude in six drug development partnerships
AIAnthropic says its life sciences team has run deep research partnerships with six drug developers over several months and has started its own discovery programs. The case studies report that Claude proposed a Generate Biomedicines CAR T-cell design about 70% shorter than standard, which in lab tests made immune cells produce roughly 10 times as many receptors. Anthropic also says the work is still largely preclinical, with clinical trial involvement planned as programs advance.